DD for Daddy, let's talk about $ATNM

Inspired by Daddy's post , I wanted to be a good boy and tell him about the DD i have been doing, scratch that, analysts posts i have been saving about $ATNM and its 900% gain potentials.

So ladies and gentleman take a seat while i copy paste from my notes..

Source 1: TipRanks :

Actinium Pharmaceuticals develops ARCs, or Antibody Radiation-Conjugates, capable of combining the targeting ability of antibodies with radiation’s cell killing ability. Given that the company recently strengthened its balance sheet, the analyst community sees its $0.21 share price as reflecting the ideal entry point.

ATNM has raised $31.6 million through equity financing in April. Maxim analyst Jason McCarthy believes that this is important because it frees the company up to focus on the Phase 3 Sierra trial, which is a single pivotal trial evaluating Iomab-B as a treatment for patients age 55 and up with r/r AML. McCarthy commented, “While it’s been a bumpy road on multiple fronts for Actinium that has pushed the shares to near its 52-week low, management has continued to execute, positioning the company for the home stretch to get to pivotal Phase 3 data.”

Looking at the data that has been released so far, McCarthy stated, “The 50% enrollment BMT numbers tell us the trial has an inherent imbalance, not by the design, but by the fact that sadly these patients are so sick that the chemo arm mostly won’t make it to BMT. This is what was observed with only 7/38 making it vs. 31/31 in the Iomab arm.” The fact that most patients had been heavily pretreated and had relapsed/refractory disease made this result unsurprising.

It should be noted that there are 80 days left to reach the six-month time for the durable complete remission (dCR) endpoint, and the Iomab arm currently has six times more patients than the chemo arm. “Assuming this trend continues to the 100 patient mark (ad hoc data analysis in 2Q20 that would be reported in 4Q20) or the top-line data for all N=150 in 2021, the probability of reaching the primary endpoint with statistical significance should favor Iomab,” McCarthy said.

This combined with a cash runway that should extend into 2021 and through both the SIERRA Phase 3 top-line data readout and potential BLA filing, McCarthy concluded, “As such, we see an attractive option for investors, in what is a tough COVID environment, to build positions in ATNM and await the interim data later this year.”

Bearing this in mind, McCarthy reiterated a Buy rating and $1.50 price target. The five-star analyst’s target implies shares could soar 603% in the next year. (To watch McCarthy’s track record, click herehere)

Like McCarthy, other analysts also take a bullish approach. ATNM’s Strong Buy consensus rating breaks down into 3 Buys and zero Holds or Sells. Given the $2.75 average price target, shares could skyrocket 1,172% in the coming twelve months. (See Actinium stock analysis on TipRanks)

Source 2: Tradingview (strong Buy indicator)

Actinium Pharmaceuticals Inc ATNM 31.41% surged 39.6% to $0.3090 after H.C. Wainwright initiated coverage on the company’s stock with a Buy rating and announced a $3 price target

Putting the money where the mouth is , i have 21000 shares of $ATNM that i purchased at 0.26 at day close yesterday.

Smile daddy smile :)

EDIT: More reasons for Daddy to be happy. Following patent got an approval today for ATNM

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020113047

EDIT: I thought it would be a responsible thing to make you aware that October 29th is when their delisting date arrives. If the stock isn’t above $1 before that, they will reverse split and we’ll lose value. So please be mindful of this and then chalk your plans accordingly. Take some profits out so that you can minimize any eventual losses.